Search results
Results From The WOW.Com Content Network
AbbVie is a member of the exclusive group of Dividend Kings -- its current streak of consecutive dividend increases stands at 52 years. The cash payout ratio is conservative at less than 49%, and ...
This top dividend growth stock is attractively priced. Even though AbbVie's stock has been a strong performer, the company's shares only trade at 15.2 times forward earnings. That's a significant ...
AbbVie qualifies as a high-yield stock, with shares paying a 3.06% annualized yield. But its 51.3 P/E ratio may limit share-price appreciation in the near term. Don’t miss this second chance at ...
AbbVie Inc. is an American pharmaceutical company headquartered in North Chicago, Illinois. It is ranked sixth on the list of largest biomedical companies by revenue. In 2023, the company's seat in Forbes Global 2000 was 74. [ 2] The company's primary product is Humira (adalimumab) ($14 billion in 2023 revenues, 27 percent of total ...
These stocks have increased their dividends for at least 50 consecutive years. AbbVie is a member of dividend royalty thanks to its track record of 52 years in a row of dividend hikes.
The S&P 500 Dividend Aristocrats is a stock market index composed of the companies in the S&P 500 index that have increased their dividends in each of the past 25 consecutive years. It was launched in May 2005. [1]
The stock yields 3.7%, and management has raised the dividend by an average of 7.8% over the past three years. Investors can also sleep well at night holding AbbVie, thanks to a modest 55% payout ...
AbbVie (NYSE:ABBV) was spun off from Abbott Laboratories in 2013 but has maintained an increasing dividend since, with a forward dividend of $5.92 and a yield of 4.01%.